

BIOGEN IDEC INC
Form 3
June 27, 2005

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â Arner Raymond G		(Month/Day/Year)	BIOGEN IDEC INC [BIIB]	
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
14 CAMBRIDGE CENTER			(Check all applicable)	
(Street)			<input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below) Acting General Counsel	
CAMBIRIDGE,Â MAÂ 02142			6. Individual or Joint/Group Filing(Check Applicable Line)	
(City)	(State)	(Zip)	<input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	13,142.59 ⁽¹⁾	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of	

Edgar Filing: BIOGEN IDEC INC - Form 3

				Shares		(I) (Instr. 5)	
Stock Option (right-to-buy)	10/04/2000 ⁽²⁾	10/04/2009	Common Stock	34,500	\$ 72.5	D	Â
Stock Option (right-to-buy)	12/15/2001 ⁽³⁾	12/15/2010	Common Stock	3,450	\$ 45.46	D	Â
Stock Option (right-to-buy)	12/14/2002 ⁽⁴⁾	12/14/2011	Common Stock	17,250	\$ 49.03	D	Â
Stock Option (right-to-buy)	09/27/2003 ⁽⁵⁾	09/27/2012	Common Stock	5,750	\$ 26.45	D	Â
Stock Option (right-to-buy)	12/06/2003 ⁽⁶⁾	12/06/2012	Common Stock	13,713	\$ 37.45	D	Â
Stock Option (right-to-buy)	12/31/2004 ⁽⁷⁾	02/06/2014	Common Stock	13,000	\$ 43.5	D	Â
Stock Option (right-to-buy)	02/17/2006 ⁽⁸⁾	02/17/2015	Common Stock	9,500	\$ 67.57	D	Â
Stock Option (right-to-buy)	06/02/2006 ⁽⁹⁾	06/02/2015	Common Stock	5,000	\$ 38.07	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Arner Raymond G 14 CAMBRIDGE CENTER CAMBRIDGE, MA 02142	Â	Â	Â Acting General Counsel	Â

Signatures

By: Benjamin S. Harshbarger; For: Raymond G. Arner

06/27/2005

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Number of directly held shares consists of 1242.5870 shares acquired through the Issuer's Employee Stock Purchase Plan, and grants of 4000, 2900 and 5000 shares of Restricted Stock which fully vest on 02/06/2007, 02/17/2008, and 06/02/08 respectively.
- (2) The stock option became exercisable in five (5) equal annual installments, commencing one year after the grant date of 10/04/99.
- (3) The stock option became exercisable in five (5) equal annual installments, commencing one year after the grant date of 12/15/00.
- (4) The stock option became exercisable in four (4) equal annual installments, commencing one year after the grant date of 12/14/01.
- (5) The stock option became exercisable in four (4) equal annual installments, commencing one year after the grant date of 09/27/02.
- (6) The stock option became exercisable in four (4) equal annual installments, commencing one year after the grant date of 12/06/02.
- (7) The stock option became exercisable in four (4) equal annual installments, commencing on 12/31/2004.

Edgar Filing: BIOGEN IDEC INC - Form 3

- (8) The stock option becomes exercisable in four (4) equal annual installments, commencing one year after the grant date of 02/17/05.
- (9) The stock option becomes exercisable in four (4) equal annual installments, commencing one year after the grant date of 06/02/05.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.